Nelkin B D, Ball D W
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Oncol Rep. 2001 Jan-Feb;8(1):157-60. doi: 10.3892/or.8.1.157.
Medullary thyroid carcinoma (MTC), both in patients and in preclinical models, is resistant to chemotherapy. In this study, we show that the anti-neovascular agent combretastatin A-4 phosphate prodrug (CA4P) in combination with doxorubicin was effective in curtailing tumor growth in a preclinical model of human MTC. This combination of combretastatin and doxorubicin extended the doubling time of established MTC tumors in nude mice to 29 days, compared to 12 days in untreated controls. This suggests that a combination of combretastatin and a cytotoxic chemotherapeutic agent may be an effective treatment for MTC.
甲状腺髓样癌（MTC）患者以及临床前模型对化疗均具有抗性。在本研究中，我们发现抗血管生成药物磷酸考布他汀A - 4前药（CA4P）与阿霉素联合使用，在人MTC临床前模型中对抑制肿瘤生长有效。考布他汀与阿霉素的这种联合用药，使裸鼠体内已形成的MTC肿瘤倍增时间延长至29天，而未治疗对照组为12天。这表明考布他汀与细胞毒性化疗药物联合使用可能是MTC的一种有效治疗方法。
